DE69719755T2 - Polymorphe verbindungen - Google Patents

Polymorphe verbindungen

Info

Publication number
DE69719755T2
DE69719755T2 DE69719755T DE69719755T DE69719755T2 DE 69719755 T2 DE69719755 T2 DE 69719755T2 DE 69719755 T DE69719755 T DE 69719755T DE 69719755 T DE69719755 T DE 69719755T DE 69719755 T2 DE69719755 T2 DE 69719755T2
Authority
DE
Germany
Prior art keywords
pct
fluvastatin sodium
fluvastatin
sodium form
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69719755T
Other languages
English (en)
Other versions
DE69719755D1 (de
Inventor
Karol Horvath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Pharma GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9602477A external-priority patent/SE9602477D0/xx
Priority claimed from SE9700751A external-priority patent/SE9700751D0/xx
Application filed by Novartis Pharma GmbH, Novartis AG filed Critical Novartis Pharma GmbH
Publication of DE69719755D1 publication Critical patent/DE69719755D1/de
Application granted granted Critical
Publication of DE69719755T2 publication Critical patent/DE69719755T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69719755T 1996-06-24 1997-06-18 Polymorphe verbindungen Expired - Lifetime DE69719755T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9602477A SE9602477D0 (sv) 1996-06-24 1996-06-24 Polymorphic compounds
SE9700751A SE9700751D0 (sv) 1997-03-03 1997-03-03 Polymorphic compounds
PCT/SE1997/001097 WO1997049681A1 (en) 1996-06-24 1997-06-18 Polymorphic compounds

Publications (2)

Publication Number Publication Date
DE69719755D1 DE69719755D1 (de) 2003-04-17
DE69719755T2 true DE69719755T2 (de) 2003-11-20

Family

ID=26662685

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69719755T Expired - Lifetime DE69719755T2 (de) 1996-06-24 1997-06-18 Polymorphe verbindungen

Country Status (11)

Country Link
US (1) US6124340A (de)
EP (1) EP0907639B1 (de)
JP (2) JP4282092B2 (de)
AT (1) ATE234282T1 (de)
AU (1) AU3366297A (de)
CY (1) CY2461B1 (de)
DE (1) DE69719755T2 (de)
DK (1) DK0907639T3 (de)
ES (1) ES2194202T3 (de)
PT (1) PT907639E (de)
WO (1) WO1997049681A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902202D0 (sv) 1999-06-10 1999-06-10 Astra Ab Production of aggregates
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
EP1330435B1 (de) 2000-10-31 2005-08-24 Ciba SC Holding AG Kristalline formen von fluvastatin sodium
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
WO2003013512A2 (en) 2001-08-03 2003-02-20 Ciba Specialty Chemicals Holding Inc. Crystalline forms of fluvastatin sodium
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
DE10316087A1 (de) * 2003-04-08 2004-11-11 Ratiopharm Gmbh Polymorphstabilisierung von Fluvastatin-Natrium in Pharmazeutischen Formulierungen
WO2004096765A2 (en) * 2003-05-01 2004-11-11 Morepen Laboratories Ltd. A novel crystalline polymorph of fluvastatin sodium and a process for preparing it
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
PL1638937T3 (pl) * 2003-06-18 2009-06-30 Teva Pharmaceutical Industries Ltd Krystaliczna postać XIV soli sodowej fluwastatyny, sposoby jej wytwarzania, kompozycje farmaceutyczne zawierające tę postać oraz sposoby ich stosowania
US7368581B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Process for the preparation of fluvastatin sodium crystal from XIV
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
WO2005037787A1 (en) * 2003-10-16 2005-04-28 Ciba Specialty Chemicals Holding Inc. Crystalline form of fluvastatin sodium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
EP1784504A2 (de) * 2004-07-21 2007-05-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) C463a-polymorphismus des oatp-c-gens als grundlage für das variable ansprechen auf die statintherapie
US7371906B2 (en) * 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
WO2006021967A1 (en) * 2004-08-26 2006-03-02 Biocon Limited Process for the preparation of fluvastatin sodium form a.
WO2006030304A2 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof
JP2008515878A (ja) * 2004-10-05 2008-05-15 バイオコン・リミテッド アモルファス型フルバスタチンナトリウムの製造方法
US7795451B2 (en) * 2005-02-11 2010-09-14 Jubilant Organosys Limited Polymorphic forms of fluvastatin sodium and process for preparing the same
WO2006109147A1 (en) * 2005-04-12 2006-10-19 Glenmark Pharmaceuticals Limited Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same
MX2007013286A (es) * 2006-02-27 2008-03-07 Teva Pharma Formas novedosas de sodio de fluvastatina y preparacion de ellas.
EP1847529B1 (de) 2006-04-20 2009-05-20 F.I.S. Fabbrica Italiana Sintetici S.P.A. Verfahren zur Herstellung von Fluvastatin-Natrium
CN101250153B (zh) * 2008-02-26 2013-09-18 深圳信立泰药业股份有限公司 一种制备氟伐他汀钠晶型的工艺
ES2398802T3 (es) * 2009-04-15 2013-03-21 Pharmathen S.A. Procedimiento mejorado para la preparación de fluvastatina y sales de la misma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002131A1 (en) * 1982-11-22 1984-06-07 Sandoz Ag Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them

Also Published As

Publication number Publication date
EP0907639A1 (de) 1999-04-14
ATE234282T1 (de) 2003-03-15
ES2194202T3 (es) 2003-11-16
JP4282092B2 (ja) 2009-06-17
DE69719755D1 (de) 2003-04-17
WO1997049681A1 (en) 1997-12-31
JP2009149654A (ja) 2009-07-09
PT907639E (pt) 2003-06-30
CY2461B1 (en) 2005-06-03
AU3366297A (en) 1998-01-14
US6124340A (en) 2000-09-26
EP0907639B1 (de) 2003-03-12
DK0907639T3 (da) 2003-06-23
JP2000512992A (ja) 2000-10-03

Similar Documents

Publication Publication Date Title
DE69719755D1 (de) Polymorphe verbindungen
SI1509232T1 (sl) Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
LU91751I2 (fr) Asenapin et ses dérivés pharmaceutiquement acceptables (SYCREST®)
MA27556A1 (fr) Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
HU9601218D0 (en) Distamycin a analogue utilizable as antitumoral and antiviral medicines
ES2123149T3 (es) Derivados de perhidroisoindol como antagonistas de la substancia p.
DE60224189D1 (de) Dipeptidylpeptidase-hemmer zur behandlung von diabetes
IL116385A (en) Sulphonamides their manufacture and pharmaceutical compositions containing them
MXPA03011681A (es) Uso de inhibidores de epoxido hidrolasa soluble, para tratar enfermedades relacionadas con la enfermedad cardiovascular.
HUT77925A (hu) Dihidrobenzofuránok, azokat tartalmazó gyógyászati készítmények és eljárás előállításukra
MD1838F2 (en) 5,6-dichlorbenzimidazole derivatives, process for obtaining thereof, pharmaceutical composition and method of treatment or prevention of herpetic viral infections
NO976048D0 (no) Farmasöytiske og diett formuleringer for profylakse og behandling av mave- og tarmforstyrrelser
ES2132415T3 (es) Nuevos derivados de 5-pirrolil-2-piridilmetilsulfinilbencimidazol.
AU2672995A (en) {a}-annelated pyrrole derivatives and pharmaceutical uses thereof
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
AU3563695A (en) Novel piperidine derivatives with paf antagonist activity
BR9609847A (pt) Derivados de N-(4-Benzila-substituída)-2-aminolactam
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
BR0111102A (pt) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4pip eridinometanol ou sua pró-droga no tratamento de sintomas de demência e psicose induzida por dopamina
DK0823909T3 (da) Hidtil ukendte heterocykliske forbindelser
PT1017681E (pt) Derivados de hidrazono-benzazuleno composicoes farmaceuticas e intermediarios
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
ES2156212T3 (es) Derivados de azabicicloheptano n-substituidos como neurolepticos, etc.
NZ320522A (en) Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the compounds
ES2191170T3 (es) Nuevos (-)-enantiomeros de derivados de cis-3,4-cromano utiles en la prevencion y tratamiento de sindromes o enfermedades relacionadas con el estrogeno.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN